Q3 2025 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Increased by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT) – Zacks Research raised their Q3 2025 EPS estimates for Editas Medicine in a report issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($0.74) for the quarter, up from their prior forecast of ($0.75). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.61) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.53) EPS.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.29. Editas Medicine had a negative net margin of 196.12% and a negative return on equity of 42.95%. The company had revenue of $60.00 million for the quarter, compared to the consensus estimate of $4.84 million. During the same quarter last year, the firm posted ($0.88) earnings per share. Editas Medicine’s revenue was up 817.4% on a year-over-year basis.

EDIT has been the subject of several other research reports. StockNews.com raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. increased their price target on Editas Medicine from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 27th. Barclays raised their target price on Editas Medicine from $10.00 to $11.00 and gave the company an “equal weight” rating in a research note on Thursday, February 29th. Finally, Citigroup raised their target price on Editas Medicine from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Editas Medicine Trading Up 1.9 %

EDIT opened at $5.32 on Friday. The company has a fifty day simple moving average of $7.52 and a 200 day simple moving average of $8.32. The firm has a market cap of $437.52 million, a price-to-earnings ratio of -2.60 and a beta of 2.01. Editas Medicine has a twelve month low of $5.11 and a twelve month high of $11.91.

Hedge Funds Weigh In On Editas Medicine

A number of hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its holdings in shares of Editas Medicine by 401.9% during the 4th quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock valued at $53,000 after acquiring an additional 4,156 shares in the last quarter. Clear Street Markets LLC acquired a new position in shares of Editas Medicine in the 3rd quarter valued at about $44,000. Amalgamated Bank increased its position in Editas Medicine by 18.0% in the 3rd quarter. Amalgamated Bank now owns 8,023 shares of the company’s stock valued at $63,000 after buying an additional 1,226 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Editas Medicine by 351.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,450 shares of the company’s stock valued at $96,000 after buying an additional 7,355 shares in the last quarter. Finally, Independent Advisor Alliance bought a new stake in Editas Medicine in the 3rd quarter valued at about $81,000. Institutional investors own 71.90% of the company’s stock.

Insider Activity

In other news, SVP Baisong Mei sold 20,327 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $9.42, for a total value of $191,480.34. Following the sale, the senior vice president now directly owns 141,543 shares in the company, valued at $1,333,335.06. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Editas Medicine news, SVP Baisong Mei sold 20,327 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $9.42, for a total value of $191,480.34. Following the sale, the senior vice president now owns 141,543 shares in the company, valued at $1,333,335.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Gilmore Neil O’neill sold 77,824 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $9.42, for a total value of $733,102.08. Following the completion of the sale, the chief executive officer now owns 327,470 shares in the company, valued at approximately $3,084,767.40. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.